- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Katsinelos P et al. (2005) High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 61: 407–415
Allopurinol inhibits the generation of oxygen-derived free radicals and it has been postulated that this xanthine oxidase inhibitor might prevent post-endoscopic retrograde
cholangiopancreatography (ERCP) pancreatitis. Despite promising results in animal models, prospective studies using a standard dose of allopurinol have not been successful in humans. In a
prospective, randomized, double-blind, placebo-controlled trial, Katsinelos and colleagues found that in patients given high-dose, oral allopurinol before treatment, post-ERCP pancreatitis
occurred less frequently.
Anyone you share the following link with will be able to read this content:
